Assessment of the availability of repurposed orphan drugs in India.
India has a massive burden of rare diseases (RDs), with an estimated 96 million people living with RDs but limited options for treatment. Repurposing drugs used for other common conditions are essential alternative for RDs due to their cost-effectiveness and reduced timeline. India's patent reg...
Main Authors: | Khujith Rajueni, Mohua Chakraborty Choudhury |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLOS Global Public Health |
Online Access: | https://doi.org/10.1371/journal.pgph.0001498 |
Similar Items
-
Assessment of the availability of repurposed orphan drugs in India
by: Khujith Rajueni, et al.
Published: (2023-01-01) -
Rare disease patients in India are rarely involved in international orphan drug trials
by: Monoswi Chakraborty, et al.
Published: (2022-01-01) -
Rare disease patients in India are rarely involved in international orphan drug trials.
by: Monoswi Chakraborty, et al.
Published: (2022-01-01) -
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data.
by: Mohua Chakraborty Choudhury, et al.
Published: (2022-01-01) -
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
by: Mohua Chakraborty Choudhury, et al.
Published: (2022-01-01)